Literature DB >> 19664686

Potential association of DRD2 and DAT1 genetic variation with heroin dependence.

Qiao-Fang Hou1, Sheng-Bin Li.   

Abstract

The aim of our study was to investigate the potential association of dopamine receptor D2 gene (DRD2) TaqI RFLP A (rs1800497) and dopamine transporter gene (DAT) 3'untranslated region VNTR genetic variations with heroin addiction. Genotyping was performed using PCR-based techniques in 530 heroin abusers and 500 controls. Our results showed that DRD2 TaqI A1 allele carriers (genotypes A1A1 and A1A2) were prone to heroin abuse in models of dominance or co-dominance. We detected a 12 repeat allele and 6/6, 7/9, 9/11, 10/12 genotype in a Chinese/eastern Asian population for the first time. However, no significant differences in the DAT1 VNTR were found between the two groups in either genotypic or allelic distributions and there was no gene interaction between the two genetic loci.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19664686     DOI: 10.1016/j.neulet.2009.08.004

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  28 in total

1.  Association of dopamine receptor gene polymorphism and psychological personality traits in liability for opioid addiction.

Authors:  Nermana Mehić-Basara; Lilijana Oruč; Lejla Kapur-Pojskić; Jasmin Ramić
Journal:  Bosn J Basic Med Sci       Date:  2013-08       Impact factor: 3.363

2.  Genetic associations between ADHD and dopaminergic genes (DAT1 and DRD4) VNTRs in Korean children.

Authors:  Jun Ho Hong; In Wook Hwang; Myung Ho Lim; Ho Jang Kwon; Han Jun Jin
Journal:  Genes Genomics       Date:  2018-08-11       Impact factor: 1.839

3.  The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction.

Authors:  Toni-Kim Clarke; Amy R D Weiss; Thomas N Ferarro; Kyle M Kampman; Charles A Dackis; Helen M Pettinati; Charles P O'brien; David W Oslin; Falk W Lohoff; Wade H Berrettini
Journal:  Ann Hum Genet       Date:  2013-11-25       Impact factor: 1.670

Review 4.  Pharmacogenomics of Pain Management: The Impact of Specific Biological Polymorphisms on Drugs and Metabolism.

Authors:  Elyse M Cornett; Michelle A Carroll Turpin; Allison Pinner; Pankaj Thakur; Tamizh Selvan Gnana Sekaran; Harish Siddaiah; Jasmine Rivas; Anna Yates; G Jason Huang; Anitha Senthil; Narjeet Khurmi; Jenna L Miller; Cain W Stark; Richard D Urman; Alan David Kaye
Journal:  Curr Oncol Rep       Date:  2020-02-06       Impact factor: 5.075

Review 5.  The Mesolimbic Dopamine System in Chronic Pain and Associated Affective Comorbidities.

Authors:  Randal A Serafini; Kerri D Pryce; Venetia Zachariou
Journal:  Biol Psychiatry       Date:  2020-01-01       Impact factor: 13.382

6.  Updated findings of the association and functional studies of DRD2/ANKK1 variants with addictions.

Authors:  Yunlong Ma; Wenji Yuan; Xianzhong Jiang; Wen-Yan Cui; Ming D Li
Journal:  Mol Neurobiol       Date:  2014-08-20       Impact factor: 5.590

Review 7.  A review of opioid addiction genetics.

Authors:  Richard C Crist; Benjamin C Reiner; Wade H Berrettini
Journal:  Curr Opin Psychol       Date:  2018-08-09

Review 8.  Common and specific liability to addiction: approaches to association studies of opioid addiction.

Authors:  David A Nielsen; Mary Jeanne Kreek
Journal:  Drug Alcohol Depend       Date:  2012-04-27       Impact factor: 4.492

Review 9.  Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic.

Authors:  Rajiv Balyan; David Hahn; Henry Huang; Vidya Chidambaran
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-02-24       Impact factor: 4.481

10.  ANKK1, TTC12, and NCAM1 polymorphisms and heroin dependence: importance of considering drug exposure.

Authors:  Elliot C Nelson; Michael T Lynskey; Andrew C Heath; Naomi Wray; Arpana Agrawal; Fiona L Shand; Anjali K Henders; Leanne Wallace; Alexandre A Todorov; Andrew J Schrage; Nancy L Saccone; Pamela A F Madden; Louisa Degenhardt; Nicholas G Martin; Grant W Montgomery
Journal:  JAMA Psychiatry       Date:  2013-03       Impact factor: 21.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.